**The primary drivers of trader sentiment center on the pace of federal administrative action following President Trump’s December 2025 executive order directing expedited rescheduling of marijuana to Schedule III.** In April 2026 the Department of Justice and DEA issued a final order that immediately moved FDA-approved marijuana products and state-licensed medical marijuana to Schedule III, while withdrawing prior proceedings and launching a new expedited hearing process on broader rescheduling. That hearing is scheduled to begin June 29, 2026, with firm procedural deadlines intended to accelerate consideration of moving additional forms of marijuana from Schedule I. These steps have already delivered partial rescheduling for medical programs, yet full implementation for all cannabis categories remains subject to the outcome of the ongoing rulemaking and any subsequent agency or court developments. Traders therefore focus on whether the June hearing produces a timely final rule or encounters delays, litigation, or further executive or congressional intervention within the market’s resolution window.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhật$791,969 KL.
Mar 31, 2026
September 30
14%
December 31
29%
$791,969 KL.
September 30
$0 KL.
14%
December 31
$182,399 KL.
29%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**The primary drivers of trader sentiment center on the pace of federal administrative action following President Trump’s December 2025 executive order directing expedited rescheduling of marijuana to Schedule III.** In April 2026 the Department of Justice and DEA issued a final order that immediately moved FDA-approved marijuana products and state-licensed medical marijuana to Schedule III, while withdrawing prior proceedings and launching a new expedited hearing process on broader rescheduling. That hearing is scheduled to begin June 29, 2026, with firm procedural deadlines intended to accelerate consideration of moving additional forms of marijuana from Schedule I. These steps have already delivered partial rescheduling for medical programs, yet full implementation for all cannabis categories remains subject to the outcome of the ongoing rulemaking and any subsequent agency or court developments. Traders therefore focus on whether the June hearing produces a timely final rule or encounters delays, litigation, or further executive or congressional intervention within the market’s resolution window.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Thị trường mở: Feb 7, 2026, 5:04 PM ET
Khối lượng
$791,969Ngày kết thúc
Mar 31, 2026Thị trường mở
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**The primary drivers of trader sentiment center on the pace of federal administrative action following President Trump’s December 2025 executive order directing expedited rescheduling of marijuana to Schedule III.** In April 2026 the Department of Justice and DEA issued a final order that immediately moved FDA-approved marijuana products and state-licensed medical marijuana to Schedule III, while withdrawing prior proceedings and launching a new expedited hearing process on broader rescheduling. That hearing is scheduled to begin June 29, 2026, with firm procedural deadlines intended to accelerate consideration of moving additional forms of marijuana from Schedule I. These steps have already delivered partial rescheduling for medical programs, yet full implementation for all cannabis categories remains subject to the outcome of the ongoing rulemaking and any subsequent agency or court developments. Traders therefore focus on whether the June hearing produces a timely final rule or encounters delays, litigation, or further executive or congressional intervention within the market’s resolution window.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Khối lượng
$791,969Ngày kết thúc
Mar 31, 2026Thị trường mở
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...**The primary drivers of trader sentiment center on the pace of federal administrative action following President Trump’s December 2025 executive order directing expedited rescheduling of marijuana to Schedule III.** In April 2026 the Department of Justice and DEA issued a final order that immediately moved FDA-approved marijuana products and state-licensed medical marijuana to Schedule III, while withdrawing prior proceedings and launching a new expedited hearing process on broader rescheduling. That hearing is scheduled to begin June 29, 2026, with firm procedural deadlines intended to accelerate consideration of moving additional forms of marijuana from Schedule I. These steps have already delivered partial rescheduling for medical programs, yet full implementation for all cannabis categories remains subject to the outcome of the ongoing rulemaking and any subsequent agency or court developments. Traders therefore focus on whether the June hearing produces a timely final rule or encounters delays, litigation, or further executive or congressional intervention within the market’s resolution window.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhật
Cẩn thận với liên kết bên ngoài.
Cẩn thận với liên kết bên ngoài.
Câu hỏi thường gặp